Medscape Medical News
Mark Crane
Sept. 13, 2013
The US Food and Drug Administration (FDA) today authorized the marketing of the UroLift
system, the first permanent implant to relieve low or blocked urine
flow in men aged 50 years and older with an enlarged prostate.
The UroLift system relieves the urine flow by pulling back the prostate tissue that is pressing on the urethra.
"The UroLift provides a less invasive alternative to treating [benign
prostatic hyperplasia] than surgery," Christy Foreman, director of the
Office of Device Evaluation at the FDA's Center for Devices and
Radiological Health, said in a release. "This device also may offer
relief to men who cannot tolerate available drug therapies."
Read the full Medscape report
(Free sign-up may be required)
